ArticleScientific reports2018
The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 81 citations in OpenAlex.
- Differential response to donepezil in MRI subtypes of mild cognitive impairment.Alzheimer's research & therapy · 2023Trial
- Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.Alzheimer's research & therapy · 2021Trial
- Cortical thickness signature of early-onset Alzheimer's disease across clinical stages and A/T1 biomarker profiles.Journal of neurology · 2026Article
- Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology.Journal of neurology · 2026Article
- Differences in cognitive performance and neuroanatomy according to Alzheimer's disease pathophysiology.Arquivos de neuro-psiquiatria · 2026Article
- Alterations in functional connectivity of the anterior cingulate cortex associated with different levels of tau and amyloid-Frontiers in neuroscience · 2026Article
- Combined use of plasma p-tau217, NfL, and GFAP predicts domain-specific cognitive decline in cognitively unimpaired and MCI individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Serum and Cerebrospinal Fluid Malondialdehyde Levels in Patients with Mild Cognitive Impairment.Journal of xenobiotics · 2025Article
- Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer's disease.Brain communications · 2025Article
- Article
- Biomarkers of neural integrity and immunoglobulin genes influence neurodegeneration in Alzheimer's disease.Journal of the neurological sciences · 2024Article
- Prospective Longitudinal Perfusion in Probable Alzheimer's Disease Correlated with Atrophy in Temporal Lobe.Aging and disease · 2024Article
- The clinical importance of suspected non-Alzheimer disease pathophysiology.Nature reviews. Neurology · 2024Review
- Multimodal subtypes identified in Alzheimer's Disease Neuroimaging Initiative participants by missing-data-enabled subtype and stage inference.Brain communications · 2024Article
- Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Amyloid PET and Brain MR Imaging Data: A 48-Month Follow-Up Analysis of the Alzheimer's Disease Neuroimaging Initiative Cohort.Diagnostics (Basel, Switzerland) · 2023Article
- Exploring the ATN classification system using brain morphology.Alzheimer's research & therapy · 2023Article
- Criterion Validation of Tau PET Staging Schemes in Relation to Cognitive Outcomes.Journal of Alzheimer's disease : JAD · 2023Article
- β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.Neurology · 2022Article
- Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer's disease.Nature communications · 2022Article
- Alpha desynchronization during Stroop test unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau.Neurobiology of aging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The objective of this study was to evaluate the A/T/N biomarker scheme in relation with brain atrophy patterns in individuals with mild cognitive impairment (MCI). Of the 154 participants with MCI, 74 progressed to AD within 36-months, and 80 remained stable. In addition, 101 cognitively healthy participants and 102 participants with AD were included. The A/T/N classification was assessed with cerebrospinal fluid markers. Each individual was rated as either positive (abnormal) or negative (normal) on each biomarker. Brain atrophy was assessed with visual ratings from magnetic resonance imaging. None of the individuals with MCI progressed to AD if they had a negative "A" biomarker in conjunction with minimal atrophy. In contrary, several individuals with MCI progressed to AD if they had a positive "A" biomarker in conjunction with minimal atrophy. Numerous individuals with MCI showed inconsistency in the neurodegeneration domain ("N") regarding t-tau and atrophy. The assessment of the A/T/N classification scheme in addition with brain atrophy patterns in MCI, increases the knowledge of the clinical trajectories and the variability within the neurodegeneration domain. This emphasises that individuals with MCI display heterogeneous longitudinal patterns closely connected to their biomarker profiles, which could have important clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.